OBJECTIVE: To evaluate the efficacy

safety and economy of azacitidine in the treatment of myelodysplastic syndrome based on rapid health technology assessment

so as to provide evidence-based evidence for drug selection and decision-makers conveniently. METHODS: Systematic review/Meta-analysis and pharmacoeconomic studies on azacitidine and control group（decitabine or other treatments） in the treatment of myelodysplastic syndrome were systematically retrieved from CNKI

Wanfang Data

PubMed

the Cochrane Library and other databases. Literature screening

data extraction and summary were performed according to the inclusion and exclusion criteria by two evaluators independently

so that the conclusion was qualitatively analyzed through qualitative description. RESULTS: Totally seven systematic review/Meta-analysis and two pharmacoeconomic studies were included. Existing evidence indicated that compared with the control group

azacitidine had a certain advantage of efficacy in the treatment of myelodysplastic syndrome without increasing patients’ hematotoxicity. Both azacitidine and decitabine had good economy in China. CONCLUSIONS: Compared with supportive treatment

the demethylation agents should be recommended for the treatment of myelodysplastic syndrome. Moreover

azacitidine is more effective than decitabine.